CompletedNot Applicable

Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure Management

Australia, India, South Korea608 participantsStarted 2025-09-18

Plain-language summary

This is a survey-based study conducted among cardiologists and nephrologists treating people with Atherosclerotic Cardiovascular Disease (ASCVD), Heart Failure (HF) and Chronic Kidney Disease (CKD). Study participants will be recruited to complete self-administered online survey. The purpose of this research is to gather real-world evidence related to attitudes around systemic inflammation and specifically the awareness, perception, drivers and barriers, and use of hsCRP in clinical practice to identify systemic inflammation in people with ASCVD+CKD and HF.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Informed consent obtained before any study related activities (study-related activities are any procedure related to recording of data according to the protocol). * Male or female, age above 18 years at the time of signing informed consent. * Is a nephrologist or cardiologist. Cardiologists may be a mix of Interventional Cardiology, Heart Failure (HF) Specialist, General Cardiology, Preventative Cardiology, Cardiac Electrophysiology, Cardio-Oncology or Echocardiography (India only). * Has been in specialty practice greater than or equal to 3 years. * If cardiologist, sees at least 15 people with Atherosclerotic Cardiovascular Disease (ASCVD) with or without Chronic Kidney Disease (CKD) per month. * If nephrologist, sees at least 20 people with ASCVD and CKD per month. Exclusion Criteria: * Previous participation in this study. Participation is defined as having given informed consent in this study. * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * If nephrologist, is only using dialysis to treat people with ASCVD and CKD. * Does not meet inclusion criteria requirements.

What they're measuring

Perceptions towards role of systemic inflammation in identification, treatment, management of ASCVD+CKD and HF

Timeframe: At the time of survey response (Day 1)

Trial details

NCT IDNCT07160829

SponsorNovo Nordisk A/S

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-10-30